Table 4 Cox regression analysis of RFS in ICC patients in the training group

Age, < 60/ ≥ 60

1.076

0.791–1.463

0.640

Gender, male/female

1.056

0.777–1.436

0.727

History of hepatitis B infection, -/ + 

0.647

0.466–0.897

0.009

1.071

0.749–1.532

0.707

Hepatolithiasis, -/ + 

0.956

0.598–1.528

0.852

ALT (U/L), < 50/ ≥ 50

1.536

1.086–2.172

0.015

1.282

0.788–2.087

0.317

AST (U/L), < 40/ ≥ 40

1.739

1.254–2.411

0.001

1.054

0.626–1.773

0.843

Bilirubin (umol/L), < 21/ ≥ 21

1.058

0.686–1.632

0.800

AFP (ng/mL), < 7/ ≥ 7

1.012

0.738–1.387

0.941

CEA (ng/mL), < 5/ ≥ 5

1.889

1.366–2.611

 < 0.001

1.473

1.006–2.158

0.047

CA19-9(U/ml), < 37/ ≥ 37

2.480

1.770–3.476

 < 0.001

1.580

1.066–2.341

0.023

Tumor differentiation, well-moderate/poor

1.790

1.240–2.583

0.002

1.368

0.915–2.047

0.127

Tumor number, 1/ ≥ 2

1.572

1.124–2.198

0.008

Tumor size (cm), < 5/ ≥ 5

1.589

1.135–2.226

0.007

TBS ≥ 6.3

1.992

1.460–2.718

 < 0.001

PT (s)

1.082

0.970–1.206

0.156

INR

0.957

0.869–1.053

0.368

APTT (s)

0.991

0.965–1.018

0.499

White blood cell count (10^9/L)

1.024

0.971–1.081

0.381

Neutrophil count (10^9/L)

1.037

0.978–1.099

0.222

HALP < 37.1

1.646

1.212–2.237

0.001

Vascular invasion, -/ + 

2.801

2.033–3.858

 < 0.001

1.804

1.211–2.689

0.004

Perineural invasion, -/ + 

1.517

1.116–2.064

0.008

1.086

0.774–1.525

0.632

Lymph node invasion, -/ + 

2.509

1.733–3.630

 < 0.001

1.991

1.340–2.958

0.001

HTS grade

 1

 2

2.204

1.517–3.204

 < 0.001

1.712

1.135–2.582

0.010

 3

3.803

2.542–5.689

 < 0.001

2.797

1.768–4.425

 < 0.001